Effective Prophylaxis with Daily Recombinant Factor VIIa (rFVIIa-Novoseven) in a Child with High Titre Inhibitors and a Target Joint

Thromb Haemost 2001; 86(04): 1126-1127
DOI: 10.1055/s-0037-1616550

Letters to the Editor

Schattauer GmbH

Ben R. Saxon

¹Department of Haematology, Women’s and Children’s Hospital, North Adelaide, Australia

,

Deborah Shanks

¹Department of Haematology, Women’s and Children’s Hospital, North Adelaide, Australia

,

Bryony C. Jory

¹Department of Haematology, Women’s and Children’s Hospital, North Adelaide, Australia

,

Vaughan Williams

¹Department of Haematology, Women’s and Children’s Hospital, North Adelaide, Australia

References
1 Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55 (Suppl. 06) 638-48.
2 Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80 (Suppl. 05) 773-8.
3 Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80 (Suppl. 06) 912-8.
4 Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105 (Suppl. 04) 1109-13.
5 Aronstam A, Arblaster PG, Rainsford SG, Turk P, Slattery M, Alderson MR, Hall DE, Kirk PJ. Prophylaxis in haemophilia: a double-blind controlled trial. Br J Haematol 1976; 33 (Suppl. 01) 81-90.